schliessen

Filtern

 

Bibliotheken

Safety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting

Background Vaccination that prevents tuberculosis (TB) disease, particularly in adolescents, would have the greatest impact on the global TB epidemic. Safety, reactogenicity and immunogenicity of the vaccine candidate M72/AS01Ewas evaluated in healthy, HIV-negative adolescents in a TB endemic region... Full description

Journal Title: Vaccine 2015-07-31, Vol.33 (32), p.4025
Main Author: Adam Penn-Nicholson
Other Authors: Hennie Geldenhuys , Wivine Burny , Robbert van der Most , Cheryl L Day , Erik Jongert , Philippe Moris , Mark Hatherill , Opokua Ofori-Anyinam , Willem Hanekom , Anne Bollaerts , Marie-Ange Demoitie , Angelique Kany Kany Luabeya , Evi De Ruymaeker , Michele Tameris , Didier Lapierre , Thomas J Scriba
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Limited
ID: ISSN: 0264-410X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_1708138933
title: Safety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting
format: Article
creator:
  • Adam Penn-Nicholson
  • Hennie Geldenhuys
  • Wivine Burny
  • Robbert van der Most
  • Cheryl L Day
  • Erik Jongert
  • Philippe Moris
  • Mark Hatherill
  • Opokua Ofori-Anyinam
  • Willem Hanekom
  • Anne Bollaerts
  • Marie-Ange Demoitie
  • Angelique Kany Kany Luabeya
  • Evi De Ruymaeker
  • Michele Tameris
  • Didier Lapierre
  • Thomas J Scriba
subjects:
  • Cytokines
  • Drug dosages
  • Health care
  • Immunization
  • Laboratories
  • Lymphocytes
  • Peptides
  • Software
  • Studies
  • Teenagers
  • Tuberculosis
  • Vaccines
ispartof: Vaccine, 2015-07-31, Vol.33 (32), p.4025
description: Background Vaccination that prevents tuberculosis (TB) disease, particularly in adolescents, would have the greatest impact on the global TB epidemic. Safety, reactogenicity and immunogenicity of the vaccine candidate M72/AS01Ewas evaluated in healthy, HIV-negative adolescents in a TB endemic region, regardless ofMycobacterium tuberculosis(M.tb) infection status. Methods In a phase II, double-blind randomized, controlled study (NCT00950612), two doses of M72/AS01Eor placebo were administered intramuscularly, one month apart. Participants were followed-up post-vaccination, for 6 months. M72-specific immunogenicity was evaluated by intracellular cytokine staining analysis of T cells and NK cells by flow cytometry. Results No serious adverse events were recorded. M72/AS01Einduced robust T cell and antibody responses, including antigen-dependent NK cell IFN-γ production. CD4 and CD8 T cell responses were sustained at 6 months post vaccination. Irrespective ofM.tbinfection status, vaccination induced a high frequency of M72-specific CD4 T cells expressing multiple combinations of Th1 cytokines, and low level IL-17. We observed rapid boosting of immune responses inM.tb-infected participants, suggesting natural infection acts as a prime to vaccination. Conclusions The clinically acceptable safety and immunogenicity profile of M72/AS01Ein adolescents living in an area with high TB burden support the move to efficacy trials.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5114431
LOCALfalse
PrimoNMBib
record
control
sourceidproquest
recordidTN_cdi_proquest_journals_1708138933
sourceformatXML
sourcesystemPC
sourcerecordid3792608241
originalsourceidFETCH-proquest_journals_17081389333
addsrcrecordideNqNjUFrwkAUhJdSoan2JxQe9Jz4XtaY9ViLxYsnPfRUWTYvssG8bd2N0H_fFPwBhYFhvhkYpZ4JC0Jazrviap3zwkWJVBU4ypg7lZGpdV5WZO5VhuVykS8IPx7UY4wdIlaaVpn63NuW0w9YacD3_SDhxOKdH1FowY3YNzYx3B5gV5fz1z3SxgvYJpw5OpYU4S_CYQ0sDffeQeSUvJxmatLac-Snm0_Vy_vm8LbNvy7he-CYjl0YLjJWR6rRkDYrrfX_Vr_Vf0uJ
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1708138933
display
typearticle
titleSafety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting
sourceAlma/SFX Local Collection
creatorAdam Penn-Nicholson ; Hennie Geldenhuys ; Wivine Burny ; Robbert van der Most ; Cheryl L Day ; Erik Jongert ; Philippe Moris ; Mark Hatherill ; Opokua Ofori-Anyinam ; Willem Hanekom ; Anne Bollaerts ; Marie-Ange Demoitie ; Angelique Kany Kany Luabeya ; Evi De Ruymaeker ; Michele Tameris ; Didier Lapierre ; Thomas J Scriba
creatorcontribAdam Penn-Nicholson ; Hennie Geldenhuys ; Wivine Burny ; Robbert van der Most ; Cheryl L Day ; Erik Jongert ; Philippe Moris ; Mark Hatherill ; Opokua Ofori-Anyinam ; Willem Hanekom ; Anne Bollaerts ; Marie-Ange Demoitie ; Angelique Kany Kany Luabeya ; Evi De Ruymaeker ; Michele Tameris ; Didier Lapierre ; Thomas J Scriba
descriptionBackground Vaccination that prevents tuberculosis (TB) disease, particularly in adolescents, would have the greatest impact on the global TB epidemic. Safety, reactogenicity and immunogenicity of the vaccine candidate M72/AS01Ewas evaluated in healthy, HIV-negative adolescents in a TB endemic region, regardless ofMycobacterium tuberculosis(M.tb) infection status. Methods In a phase II, double-blind randomized, controlled study (NCT00950612), two doses of M72/AS01Eor placebo were administered intramuscularly, one month apart. Participants were followed-up post-vaccination, for 6 months. M72-specific immunogenicity was evaluated by intracellular cytokine staining analysis of T cells and NK cells by flow cytometry. Results No serious adverse events were recorded. M72/AS01Einduced robust T cell and antibody responses, including antigen-dependent NK cell IFN-γ production. CD4 and CD8 T cell responses were sustained at 6 months post vaccination. Irrespective ofM.tbinfection status, vaccination induced a high frequency of M72-specific CD4 T cells expressing multiple combinations of Th1 cytokines, and low level IL-17. We observed rapid boosting of immune responses inM.tb-infected participants, suggesting natural infection acts as a prime to vaccination. Conclusions The clinically acceptable safety and immunogenicity profile of M72/AS01Ein adolescents living in an area with high TB burden support the move to efficacy trials.
identifier
0ISSN: 0264-410X
1EISSN: 1873-2518
2DOI: 10.1016/j.vaccine.2015.05.088
languageeng
publisherKidlington: Elsevier Limited
subjectCytokines ; Drug dosages ; Health care ; Immunization ; Laboratories ; Lymphocytes ; Peptides ; Software ; Studies ; Teenagers ; Tuberculosis ; Vaccines
ispartofVaccine, 2015-07-31, Vol.33 (32), p.4025
rightsCopyright Elsevier Limited Jul 31, 2015
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
search
creatorcontrib
0Adam Penn-Nicholson
1Hennie Geldenhuys
2Wivine Burny
3Robbert van der Most
4Cheryl L Day
5Erik Jongert
6Philippe Moris
7Mark Hatherill
8Opokua Ofori-Anyinam
9Willem Hanekom
10Anne Bollaerts
11Marie-Ange Demoitie
12Angelique Kany Kany Luabeya
13Evi De Ruymaeker
14Michele Tameris
15Didier Lapierre
16Thomas J Scriba
title
0Safety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting
1Vaccine
descriptionBackground Vaccination that prevents tuberculosis (TB) disease, particularly in adolescents, would have the greatest impact on the global TB epidemic. Safety, reactogenicity and immunogenicity of the vaccine candidate M72/AS01Ewas evaluated in healthy, HIV-negative adolescents in a TB endemic region, regardless ofMycobacterium tuberculosis(M.tb) infection status. Methods In a phase II, double-blind randomized, controlled study (NCT00950612), two doses of M72/AS01Eor placebo were administered intramuscularly, one month apart. Participants were followed-up post-vaccination, for 6 months. M72-specific immunogenicity was evaluated by intracellular cytokine staining analysis of T cells and NK cells by flow cytometry. Results No serious adverse events were recorded. M72/AS01Einduced robust T cell and antibody responses, including antigen-dependent NK cell IFN-γ production. CD4 and CD8 T cell responses were sustained at 6 months post vaccination. Irrespective ofM.tbinfection status, vaccination induced a high frequency of M72-specific CD4 T cells expressing multiple combinations of Th1 cytokines, and low level IL-17. We observed rapid boosting of immune responses inM.tb-infected participants, suggesting natural infection acts as a prime to vaccination. Conclusions The clinically acceptable safety and immunogenicity profile of M72/AS01Ein adolescents living in an area with high TB burden support the move to efficacy trials.
subject
0Cytokines
1Drug dosages
2Health care
3Immunization
4Laboratories
5Lymphocytes
6Peptides
7Software
8Studies
9Teenagers
10Tuberculosis
11Vaccines
issn
00264-410X
11873-2518
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqNjUFrwkAUhJdSoan2JxQe9Jz4XtaY9ViLxYsnPfRUWTYvssG8bd2N0H_fFPwBhYFhvhkYpZ4JC0Jazrviap3zwkWJVBU4ypg7lZGpdV5WZO5VhuVykS8IPx7UY4wdIlaaVpn63NuW0w9YacD3_SDhxOKdH1FowY3YNzYx3B5gV5fz1z3SxgvYJpw5OpYU4S_CYQ0sDffeQeSUvJxmatLac-Snm0_Vy_vm8LbNvy7he-CYjl0YLjJWR6rRkDYrrfX_Vr_Vf0uJ
startdate20150731
enddate20150731
creator
0Adam Penn-Nicholson
1Hennie Geldenhuys
2Wivine Burny
3Robbert van der Most
4Cheryl L Day
5Erik Jongert
6Philippe Moris
7Mark Hatherill
8Opokua Ofori-Anyinam
9Willem Hanekom
10Anne Bollaerts
11Marie-Ange Demoitie
12Angelique Kany Kany Luabeya
13Evi De Ruymaeker
14Michele Tameris
15Didier Lapierre
16Thomas J Scriba
generalElsevier Limited
scope
03V.
17QL
27RV
37T2
47T5
57U9
67X7
77XB
888C
988E
108AO
118C1
128FE
138FH
148FI
158FJ
168FK
178G5
18ABUWG
19AZQEC
20BBNVY
21BENPR
22BHPHI
23C1K
24DWQXO
25FYUFA
26GHDGH
27GNUQQ
28GUQSH
29H94
30HCIFZ
31K9-
32K9.
33KB0
34LK8
35M0R
36M0S
37M0T
38M1P
39M2O
40M7N
41M7P
42MBDVC
43NAPCQ
44PQEST
45PQQKQ
46PQUKI
47Q9U
sort
creationdate20150731
titleSafety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting
authorAdam Penn-Nicholson ; Hennie Geldenhuys ; Wivine Burny ; Robbert van der Most ; Cheryl L Day ; Erik Jongert ; Philippe Moris ; Mark Hatherill ; Opokua Ofori-Anyinam ; Willem Hanekom ; Anne Bollaerts ; Marie-Ange Demoitie ; Angelique Kany Kany Luabeya ; Evi De Ruymaeker ; Michele Tameris ; Didier Lapierre ; Thomas J Scriba
facets
frbrtype5
frbrgroupidcdi_FETCH-proquest_journals_17081389333
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Cytokines
1Drug dosages
2Health care
3Immunization
4Laboratories
5Lymphocytes
6Peptides
7Software
8Studies
9Teenagers
10Tuberculosis
11Vaccines
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Adam Penn-Nicholson
1Hennie Geldenhuys
2Wivine Burny
3Robbert van der Most
4Cheryl L Day
5Erik Jongert
6Philippe Moris
7Mark Hatherill
8Opokua Ofori-Anyinam
9Willem Hanekom
10Anne Bollaerts
11Marie-Ange Demoitie
12Angelique Kany Kany Luabeya
13Evi De Ruymaeker
14Michele Tameris
15Didier Lapierre
16Thomas J Scriba
collection
0ProQuest Central (Corporate)
1Bacteriology Abstracts (Microbiology B)
2Nursing & Allied Health Database
3Health and Safety Science Abstracts (Full archive)
4Immunology Abstracts
5Virology and AIDS Abstracts
6Health & Medical Collection
7ProQuest Central (purchase pre-March 2016)
8Healthcare Administration Database (Alumni)
9Medical Database (Alumni Edition)
10ProQuest Pharma Collection
11Public Health Database
12ProQuest SciTech Collection
13ProQuest Natural Science Collection
14Hospital Premium Collection
15Hospital Premium Collection (Alumni Edition)
16ProQuest Central (Alumni) (purchase pre-March 2016)
17Research Library (Alumni Edition)
18ProQuest Central (Alumni Edition)
19ProQuest Central Essentials
20Biological Science Collection
21ProQuest Central
22Natural Science Collection
23Environmental Sciences and Pollution Management
24ProQuest Central Korea
25Health Research Premium Collection
26Health Research Premium Collection (Alumni)
27ProQuest Central Student
28Research Library Prep
29AIDS and Cancer Research Abstracts
30SciTech Premium Collection
31Consumer Health Database (Alumni Edition)
32ProQuest Health & Medical Complete (Alumni)
33Nursing & Allied Health Database (Alumni Edition)
34ProQuest Biological Science Collection
35Consumer Health Database
36Health & Medical Collection (Alumni Edition)
37Healthcare Administration Database
38Medical Database
39Research Library
40Algology Mycology and Protozoology Abstracts (Microbiology C)
41Biological Science Database
42Research Library (Corporate)
43Nursing & Allied Health Premium
44ProQuest One Academic Eastern Edition
45ProQuest One Academic
46ProQuest One Academic UKI Edition
47ProQuest Central Basic
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Adam Penn-Nicholson
1Hennie Geldenhuys
2Wivine Burny
3Robbert van der Most
4Cheryl L Day
5Erik Jongert
6Philippe Moris
7Mark Hatherill
8Opokua Ofori-Anyinam
9Willem Hanekom
10Anne Bollaerts
11Marie-Ange Demoitie
12Angelique Kany Kany Luabeya
13Evi De Ruymaeker
14Michele Tameris
15Didier Lapierre
16Thomas J Scriba
formatjournal
genrearticle
ristypeJOUR
atitleSafety and immunogenicity of candidate vaccine M72/AS01Ein adolescents in a TB endemic setting
jtitleVaccine
date2015-07-31
risdate2015
volume33
issue32
spage4025
pages4025-
issn0264-410X
eissn1873-2518
abstractBackground Vaccination that prevents tuberculosis (TB) disease, particularly in adolescents, would have the greatest impact on the global TB epidemic. Safety, reactogenicity and immunogenicity of the vaccine candidate M72/AS01Ewas evaluated in healthy, HIV-negative adolescents in a TB endemic region, regardless ofMycobacterium tuberculosis(M.tb) infection status. Methods In a phase II, double-blind randomized, controlled study (NCT00950612), two doses of M72/AS01Eor placebo were administered intramuscularly, one month apart. Participants were followed-up post-vaccination, for 6 months. M72-specific immunogenicity was evaluated by intracellular cytokine staining analysis of T cells and NK cells by flow cytometry. Results No serious adverse events were recorded. M72/AS01Einduced robust T cell and antibody responses, including antigen-dependent NK cell IFN-γ production. CD4 and CD8 T cell responses were sustained at 6 months post vaccination. Irrespective ofM.tbinfection status, vaccination induced a high frequency of M72-specific CD4 T cells expressing multiple combinations of Th1 cytokines, and low level IL-17. We observed rapid boosting of immune responses inM.tb-infected participants, suggesting natural infection acts as a prime to vaccination. Conclusions The clinically acceptable safety and immunogenicity profile of M72/AS01Ein adolescents living in an area with high TB burden support the move to efficacy trials.
copKidlington
pubElsevier Limited
doi10.1016/j.vaccine.2015.05.088